59th American Society of Hematology (ASH) Annual Meeting & Exposition
The ASH Annual Meeting & Exposition is the world’s premier event in malignant and non-malignant hematology. The event brings together professionals from around the globe to showcase the latest research in the field, provide an invaluable educational experience for those attending and allow for the opportunity to network face-to-face.
Karyopharm is again present with its own booth at this year’s ASH event. Nine presentations related to Karyopharm’s lead SINE programs, selinexor and eltanexor (KPT-8602), are being presented.
Sign up for the Karyopharm eNewsletter
Karyopharm Activities at ASH 2017
Visit Karyopharm’s booth #3215 at this year’s ASH meeting to learn more about selinexor, SINE technology and our clinical trials pipeline including the STORM, BOSTON and SADAL trials.
Karyopharm Abstracts at ASH 2017
You may also be interested in…
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
Kuruvilla J, et al – 2016
SAIL: Phase II Results of Ara-c and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML
Fiedler W, et al – 2016
Selinexor is being evaluated in a number of later phase studies across a variety of hematological and solid tumour malignancies. Our broader therapeutic pipeline of SINE compounds and dual PAK 4/NAMPT inhibitors shows our commitment to developing first-in-class drugs targeting nuclear transport and related targets in cancer and other major diseases.
American Society of Clinical Oncology (ASCO) Annual Meeting 2018
June 1-5, 2018
Chicago, IL, USA
European Hematology Association (EHA) Congress 2018
June 14-17, 2018
American Society of Hematology (ASH) Annual Meeting & Exposition 2018
December 1-4, 2018
San Diego, CA, USA